Five Prime Therapeutics (FPRX) Stock Price, News & Analysis

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $38.00 to $38.00
• 50-Day Range: $37.65 to $38.00
• 52-Week Range: $2.61 to $38.90
• Volume: N/A
• Average Volume: 1.98 million shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FPRX Stock Analysis - Frequently Asked Questions

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its quarterly earnings data on Friday, November, 6th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $3.50 million. Five Prime Therapeutics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 554.71%.
Read the conference call transcript.

What other stocks do shareholders of Five Prime Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), OPKO Health (OPK), Pfizer (PFE), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 11/06/2020
• Today: 1/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FPRX
• CUSIP: N/A
• CIK: 1175505
• Web: www.fiveprime.com
• Phone: 415-365-5600
• Fax: N/A
• Employees: 87
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-137,200,000.00
• Net Margins: -554.71%
• Pretax Margin: N/A
• Return on Equity: -75.84%
• Return on Assets: -49.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.35
• Quick Ratio: 5.35

Sales & Book Value

• Annual Sales: $14.87 million
• Price / Sales: 119.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.13 per share
• Price / Book: 9.20

Miscellaneous

• Outstanding Shares: 46,572,000
• Free Float: N/A
• Market Cap: $1.77 billion
• Optionable: Optionable
• Beta: 4.40